Barton F Haynes

List of Publications by Citations

260 papers	21,814 citations	71 h-index	143 g-index
277 ext. papers	26,348 ext. citations	14.8 avg, IF	6.74 L-index

#	Paper	IF	Citations
260	Changes in thymic function with age and during the treatment of HIV infection. *Nature*, **1998**, 396, 690-5	50.4	1587
259	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 7552-7	11.5	1472
258	Immune-correlates analysis of an HIV-1 vaccine efficacy trial. *New England Journal of Medicine*, **2012**, 366, 1275-86	59.2	1400
257	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. *Nature*, **2013**, 496, 469-76	50.4	759
256	Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. *Science*, **2005**, 308, 1906-8	33.3	612
255	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. *Journal of Experimental Medicine*, **2009**, 206, 1273-89	16.6	600
254	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. *Nature*, **2014**, 514, 455-61	50.4	576
253	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. *Nature*, **2017**, 543, 248-251	50.4	502
252	Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. *Journal of Virology*, **2008**, 82, 12449-63	6.6	452
251	The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. *Annual Review of Immunology*, **2000**, 18, 529-60	34.7	397
250	HIV-1 neutralizing antibodies: understanding nature's pathways. *Immunological Reviews*, **2013**, 254, 225-44	11.3	368
249	B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. *Nature Biotechnology*, **2012**, 30, 423-33	44.5	351
248	Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. *Journal of Virology*, **2011**, 85, 9998-10009	6.6	342
247	Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. *Immunity*, **2013**, 38, 176-86	32.3	319
246	Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. *Immunity*, **2013**, 39, 245-58	32.3	254
245	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. *Cell Host and Microbe*, **2021**, 29, 529-539.e3	23.4	225
244	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. *Cell*, **2015**, 161, 1280-92	56.2	219

243	Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. *Cell*, **2014**, 158, 481-91	56.2	213
242	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. *Journal of Experimental Medicine*, **2018**, 215, 1571-1588	16.6	212
241	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. *Cell*, **2016**, 165, 449-63	56.2	209
240	Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. *Journal of Virology*, **2014**, 88, 12669-82	6.6	198
239	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. *Cell Host and Microbe*, **2021**, 29, 23-31.e4	23.4	198
238	Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. *Cell Host and Microbe*, **2014**, 16, 105-14	23.4	192
237	Human T lymphocyte antigens as defined by monoclonal antibodies. *Immunological Reviews*, **1981**, 57, 127-61	11.3	185
236	High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. *Journal of Virological Methods*, **2009**, 158, 171-9	2.6	181
235	Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment. *Arthritis and Rheumatism*, **1989**, 32, 22-30		180
234	Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. *Journal of Experimental Medicine*, **2011**, 208, 2237-49	16.6	166
233	Latency reversal and viral clearance to cure HIV-1. *Science*, **2016**, 353, aaf6517	33.3	159
232	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. *Journal of Virology*, **2016**, 90, 76-91	6.6	151
231	HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. *Science*, **2015**, 349, aab1253	33.3	144
230	Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 181-6	11.5	144
229	Immune correlates of vaccine protection against HIV-1 acquisition. *Science Translational Medicine*, **2015**, 7, 310rv7	17.5	142
228	Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. *Arthritis and Rheumatism*, **1991**, 34, 1434-43		142
227	HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. *Journal of Virology*, **2014**, 88, 7715-26	6.6	140
226	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E3413-22	11.5	132

225	Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. *Journal of Virology*, **2012**, 86, 4688-92	6.6	132
224	A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. *Immunity*, **2020**, 53, 724-732.e7	32.3	132
223	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. *Cell*, **2016**, 166, 1471-1484.e18	56.2	132
222	Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. *Science Translational Medicine*, **2017**, 9,	17.5	127
221	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. *Nature Structural and Molecular Biology*, **2016**, 23, 81-90	17.6	126
220	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. *Cell Reports*, **2017**, 19, 719-732	10.6	123
219	Polyreactivity and autoreactivity among HIV-1 antibodies. *Journal of Virology*, **2015**, 89, 784-98	6.6	123
218	Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopesQ accessibility. *Journal of Proteome Research*, **2008**, 7, 1660-74	5.6	123
217	Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. *PLoS ONE*, **2011**, 6, e23532	3.7	123
216	D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction. *Cell Reports*, **2021**, 34, 108630	10.6	123
215	Antibody polyspecificity and neutralization of HIV-1: A hypothesis. *Human Antibodies*, **2006**, 14, 59-67	1.3	120
214	Ontogeny of the human thymus during fetal development. *Journal of Clinical Immunology*, **1987**, 7, 81-97	5.7	119
213	Viral receptor-binding site antibodies with diverse germline origins. *Cell*, **2015**, 161, 1026-1034	56.2	114
212	Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. *Journal of Infectious Diseases*, **2015**, 211, 947-55	7	111
211	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. *PLoS Pathogens*, **2015**, 11, e1005042	7.6	111
210	HIV-Host Interactions: Implications for Vaccine Design. *Cell Host and Microbe*, **2016**, 19, 292-303	23.4	108
209	The human thymus during aging. *Immunologic Research*, **2000**, 22, 253-61	4.3	108
208	Antibody polyspecificity and neutralization of HIV-1: a hypothesis. *Human Antibodies*, **2005**, 14, 59-67	1.3	103

207	Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. *Immunological Reviews*, **2017**, 275, 145-160	11.3	102
206	Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. *Cell Host and Microbe*, **2014**, 16, 304-13	23.4	99
205	Prospects for a safe COVID-19 vaccine. *Science Translational Medicine*, **2020**, 12,	17.5	99
204	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. *Nature Communications*, **2017**, 8, 15711	17.4	94
203	Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E590-E599	11.5	92
202	CD4 mimetics sensitize HIV-1-infected cells to ADCC. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E2687-94	11.5	89
201	In´vitro and in´vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. *Cell*, **2021**, 184, 4203-4219.e32	56.2	89
200	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. *Science Immunology*, **2017**, 2,	28	86
199	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. *Nature*, **2021**, 594, 553-559	50.4	85
198	Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies. *Science Immunology*, **2016**, 1, aag0851	28	82
197	Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. *Journal of Proteome Research*, **2009**, 8, 4231-42	5.6	82
196	HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. *Cell Host and Microbe*, **2014**, 16, 215-226	23.4	81
195	Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. *Expert Review of Vaccines*, **2006**, 5, 579-95	5.2	81
194	Multiple roles for HIV broadly neutralizing antibodies. *Science Translational Medicine*, **2019**, 11,	17.5	77
193	Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation. *Frontiers in Immunology*, **2014**, 5, 170	8.4	77
192	Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. *Nature Medicine*, **2016**, 22, 1465-1469	50.5	73
191	Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. *Nature Medicine*, **2018**, 24, 1590-1598	50.5	73
190	The quest for an antibody-based HIV vaccine. *Immunological Reviews*, **2017**, 275, 5-10	11.3	71

189	Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. *PLoS Computational Biology*, **2010**, 6, e1000955	5	71
188	Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. *Cell*, **2020**, 181, 1458-1463	56.2	70
187	New approaches to HIV vaccine development. *Current Opinion in Immunology*, **2015**, 35, 39-47	7.8	70
186	Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. *Expert Review of Vaccines*, **2006**, 5, 347-63	5.2	69
185	Developing an HIV vaccine. *Science*, **2017**, 355, 1129-1130	33.3	68
184	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. *Cell Reports*, **2017**, 21, 3681-3690	10.6	67
183	Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. *Journal of Virology*, **2017**, 91,	6.6	65
182	Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. *Science Translational Medicine*, **2016**, 8, 336ra62	17.5	65
181	Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 18214-9	11.5	65
180	Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. *Cell Reports*, **2018**, 25, 893-908.e7	10.6	65
179	Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 10275-80	11.5	63
178	Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein. *Journal of the American Society for Mass Spectrometry*, **2008**, 19, 1209-20	3.5	63
177	Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. *Journal of Immunology*, **2013**, 191, 1260-75	5.3	62
176	Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. *Science*, **2019**, 366,	33.3	60
175	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. *Science Translational Medicine*, **2017**, 9,	17.5	59
174	AIDS/HIV. Host controls of HIV neutralizing antibodies. *Science*, **2014**, 344, 588-9	33.3	58
173	The human thymus. A chimeric organ comprised of central and peripheral lymphoid components. *Immunologic Research*, **1998**, 18, 175-92	4.3	58
172	Critical issues in mucosal immunity for HIV-1 vaccine development. *Journal of Allergy and Clinical Immunology*, **2008**, 122, 3-9; quiz 10-1	11.5	56

171	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. *Cell Host and Microbe*, **2019**, 25, 59-72.e8	23.4	56
170	Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. *Cell Host and Microbe*, **2018**, 23, 759-765.e6	23.4	55
169	Synovial microenvironment-T cell interactions. Human T cells bind to fibroblast-like synovial cells in vitro. *Arthritis and Rheumatism*, **1988**, 31, 947-55		55
168	Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines. *Journal of the American Chemical Society*, **2013**, 135, 13113-20	16.4	54
167	Host controls of HIV broadly neutralizing antibody development. *Immunological Reviews*, **2017**, 275, 79-88	11.3	53
166	Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques. *Molecular Therapy - Nucleic Acids*, **2019**, 15, 36-47	10.7	53
165	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. *Cell Host and Microbe*, **2015**, 18, 354-62	23.4	53
164	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. *Nature Communications*, **2017**, 8, 1732	17.4	52
163	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. *Cell Reports*, **2017**, 18, 2175-2188	10.6	50
162	Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. *Immunity*, **2014**, 41, 909-18	32.3	50
161	Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. *Journal of Virology*, **2011**, 85, 7719-29	6.6	50
160	Progress in HIV-1 vaccine development. *Journal of Allergy and Clinical Immunology*, **2014**, 134, 3-10; quiz 11	11.5	49
159	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. *Science*, **2021**, 373, 991-998	33.3	48
158	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. *Nature Communications*, **2018**, 9, 1928	17.4	46
157	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. *Cell Reports*, **2016**, 14, 43-54	10.6	45
156	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. *Journal of Virology*, **2016**, 90, 5899-5914	6.6	45
155	Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. *Cell Reports*, **2018**, 25, 107-117.e3	10.6	45
154	High throughput functional analysis of HIV-1 env genes without cloning. *Journal of Virological Methods*, **2007**, 143, 104-11	2.6	44

153	Immunogenic Stimulus for Germline Precursors of Antibodies that Engage the Influenza Hemagglutinin Receptor-Binding Site. *Cell Reports*, **2015**, 13, 2842-50	10.6	43
152	Structure and Diversity of the Rhesus Macaque Immunoglobulin Loci through Multiple Genome Assemblies. *Frontiers in Immunology*, **2017**, 8, 1407	8.4	42
151	Progress in HIV-1 vaccine development. *Current Opinion in HIV and AIDS*, **2013**, 8, 326-32	4.2	42
150	RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses. *Cell*, **2018**, 175, 387-399.e17	56.2	42
149	Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy. *AIDS Research and Human Retroviruses*, **2001**, 17, 1635-43	1.6	41
148	CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies. *Journal of Virology*, **2014**, 88, 6542-55	6.6	40
147	BCR and Endosomal TLR Signals Synergize to Increase AID Expression and Establish Central B Cell Tolerance. *Cell Reports*, **2017**, 18, 1627-1635	10.6	39
146	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. *Immunity*, **2019**, 50, 677-691.e13	32.3	38
145	The human thymus. A chimeric organ comprised of central and peripheral lymphoid components. *Immunologic Research*, **1998**, 18, 61-78	4.3	38
144	Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. *Virology*, **2006**, 345, 44-55	3.6	37
143	Human erythrocyte antigens. III. Characterization of a panel of murine monoclonal antibodies that react with human erythrocyte and erythroid precursor membranes. *Vox Sanguinis*, **1987**, 52, 236-43	3.1	37
142	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. *Journal of Virology*, **2015**, 89, 6462-80	6.6	35
141	B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. *Trends in Molecular Medicine*, **2011**, 17, 108-16	11.5	35
140	Cytokines and adhesion molecules in the pathogenesis of vasculitis. *Current Rheumatology Reports*, **2000**, 2, 402-10	4.9	34
139	Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. *PLoS ONE*, **2016**, 11, e0157409	3.7	34
138	Cold sensitivity of the SARS-CoV-2 spike ectodomain. *Nature Structural and Molecular Biology*, **2021**, 28, 128-131	17.6	34
137	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. *PLoS Pathogens*, **2019**, 15, e1008026	7.6	33
136	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. *Journal of Virology*, **2018**, 92,	6.6	33

135	Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF. *Biochemistry*, **1996**, 35, 5158-65	3.2	32
134	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. *Immunity*, **2018**, 49, 1162-1174.e8	32.3	32
133	Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. *Journal of Virology*, **2015**, 89, 7813-28	6.6	31
132	Increase in TCR gamma delta T lymphocytes in synovia from rheumatoid arthritis patients with active synovitis. *Journal of Clinical Immunology*, **1992**, 12, 130-8	5.7	31
131	Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques. *JCI Insight*, **2019**, 4,	9.9	31
130	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. *Journal of Virology*, **2017**, 91,	6.6	30
129	Leukemia-associated arthritis: identification of leukemic cells in synovial fluid using monoclonal and polyclonal antibodies. *Arthritis and Rheumatism*, **1984**, 27, 1306-8		30
128	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. *EBioMedicine*, **2016**, 14, 97-111	8.8	29
127	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines **2021**,		29
126	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. *EBioMedicine*, **2016**, 12, 196-207	8.8	28
125	IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria. *PLoS ONE*, **2014**, 9, e90725	3.7	28
124	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. *Molecular Therapy*, **2016**, 24, 2021-2032	11.7	28
123	Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. *Journal of Virology*, **2016**, 90, 5031-5046	6.6	27
122	Contribution of proteasome-catalyzed peptide -splicing to viral targeting by CD8 T cells in HIV-1 infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 24748-24759	11.5	27
121	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. *PLoS ONE*, **2019**, 14, e0215163	3.7	25
120	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. *Journal of Virology*, **2018**, 92,	6.6	25
119	Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 8614-8619	11.5	25
118	Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. *PLoS ONE*, **2016**, 11, e0157391	3.7	25

117	SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. *Annual Review of Medicine*, **2021**,	17.4	25
116	Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates. *PLoS Biology*, **2019**, 17, e3000328	9.7	24
115	Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements. *Nature Communications*, **2020**, 11, 520	17.4	24
114	A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. *Nature Communications*, **2018**, 9, 2363	17.4	24
113	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. *Nature Communications*, **2019**, 10, 2898	17.4	24
112	Is developing an HIV-1 vaccine possible?. *Current Opinion in HIV and AIDS*, **2010**, 5, 362-7	4.2	24
111	Normalization of the peripheral blood T cell receptor V beta repertoire after cultured postnatal human thymic transplantation in DiGeorge syndrome. *Journal of Clinical Immunology*, **1997**, 17, 167-75	5.7	24
110	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. *Science Translational Medicine*, **2021**, eabj7125	17.5	24
109	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. *Cell Reports Medicine*, **2021**, 2, 100313	18	24
108	HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. *PLoS Pathogens*, **2014**, 10, e1004073	7.6	23
107	Designing synthetic vaccines for HIV. *Expert Review of Vaccines*, **2015**, 14, 815-31	5.2	22
106	Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. *Nature Immunology*, **2020**, 21, 199-209	19.1	22
105	Aggregate complexes of HIV-1 induced by multimeric antibodies. *Retrovirology*, **2014**, 11, 78	3.6	22
104	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. *Cell*, **2021**, 184, 2955-2972.e25	56.2	22
103	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. *Science*, **2021**, 371,	33.3	22
102	Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization. *Mucosal Immunology*, **2017**, 10, 228-237	9.2	21
101	Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. *Virology*, **2015**, 475, 37-45	3.6	21
100	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. *Journal of Virology*, **2016**, 90, 4951-4965	6.6	21

99	Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. *Journal of Virology*, **2017**, 91,	6.6	21
98	Improving Mycobacterium bovis bacillus Calmette-Guﬁn as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells. *PLoS ONE*, **2014**, 9, e108383	3.7	21
97	HIV-1 hides an AchillesQheel in virion lipids. *Immunity*, **2008**, 28, 10-2	32.3	21
96	Analysis of Fc gamma receptors on human peripheral blood leukocytes by flow microfluorometry. I. Receptor distributions on monocytes, T gamma cells and cells labeled with the 3Al anti-T cell monoclonal antibody. *European Journal of Immunology*, **1982**, 12, 474-9	6.1	21
95	A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. *Cell Reports*, **2016**, 15, 1505-1513	10.6	21
94	The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template. *Cell Reports*, **2019**, 27, 2426-2441.e6	10.6	20
93	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. *Viruses*, **2015**, 7, 5443-75	6.2	20
92	Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies. *Vaccines*, **2014**, 2, 1-14	5.3	20
91	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates **2020**,		20
90	Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. *Cell Reports*, **2021**, 35, 109179	10.6	20
89	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. *PLoS Pathogens*, **2018**, 14, e1007431	7.6	20
88	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. *Journal of Virology*, **2017**, 91,	6.6	19
87	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. *Cell Reports*, **2020**, 31, 107624	10.6	19
86	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. *Npj Vaccines*, **2021**, 6, 50	9.5	19
85	Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. *Journal of Virology*, **2018**, 92,	6.6	19
84	Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies. *Nature Communications*, **2019**, 10, 654	17.4	18
83	HIV mRNA Vaccines-Progress and Future Paths. *Vaccines*, **2021**, 9,	5.3	18
82	HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope. *Nature Communications*, **2018**, 9, 1111	17.4	17

81	The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells. *Journal of Immunological Methods*, **2014**, 409, 21-30	2.5	17
80	In vivo models of human lymphopoiesis and autoimmunity in severe combined immune deficient mice. *Journal of Clinical Immunology*, **1992**, 12, 311-24	5.7	17
79	Rheumatoid arthritis and sterile corneal ulceration. Analysis of tissue immune effector cells and ocular epithelial antigens using monoclonal antibodies. *Arthritis and Rheumatism*, **1984**, 27, 606-14		17
78	Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. *Journal of Virology*, **2017**, 91,	6.6	16
77	Distribution of CD44 variant isoforms in human skin: differential expression in components of benign and malignant epithelia. *Journal of Cutaneous Pathology*, **1995**, 22, 536-45	1.7	16
76	Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants. *MBio*, **2020**, 11,	7.8	15
75	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. *Communications Biology*, **2018**, 1, 134	6.7	15
74	Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors. *Vaccine Journal*, **2015**, 22, 726-41		14
73	Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. *Journal of Virology*, **2014**, 88, 9406-17	6.6	14
72	Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. *AIDS Research and Human Retroviruses*, **2017**, 33, 428-431	1.6	14
71	HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention?. *Nature Structural and Molecular Biology*, **2010**, 17, 543-5	17.6	14
70	Self-tolerance curtails the B cell repertoire to microbial epitopes. *JCI Insight*, **2019**, 4,	9.9	14
69	Broadly Neutralizing Antibodies and the Development of Vaccines. *JAMA - Journal of the American Medical Association*, **2015**, 313, 2419-20	27.4	13
68	Glycoengineering HIV-1 Env creates ‘supercharged’ and ‘hybrid’ glycans to increase neutralizing antibody potency, breadth and saturation. *PLoS Pathogens*, **2018**, 14, e1007024	7.6	12
67	HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. *Journal of Virology*, **2017**, 91,	6.6	12
66	Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users. *Open Forum Infectious Diseases*, **2014**, 1, ofu056	1	12
65	Gene deletions in Mycobacterium bovis BCG stimulate increased CD8+ T cell responses. *Infection and Immunity*, **2014**, 82, 5317-26	3.7	12
64	Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. *Journal of Clinical Investigation*, **2020**, 130, 5157-5170	15.9	12

63	Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. *EBioMedicine*, **2015**, 2, 713-22	8.8	11
62	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. *PLoS ONE*, **2017**, 12, e0176428	3.7	11
61	Preexisting compensatory amino acids compromise fitness costs of a HIV-1 T cell escape mutation. *Retrovirology*, **2014**, 11, 101	3.6	11
60	HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. *JCI Insight*, **2020**, 5,	9.9	11
59	Chimeric spike mRNA vaccines protect against Sarbecoviru challenge in mice **2021**,		11
58	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. *Cell Reports*, **2020**, 30, 1553-1569.e6	10.6	10
57	Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection. *Frontiers in Microbiology*, **2018**, 9, 1326	5.7	10
56	Redemption of autoreactive B cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 9022-3	11.5	10
55	Recombinant Mycobacterium bovis bacillus Calmette-Guﬁn vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques. *Vaccine Journal*, **2014**, 21, 1385-95		10
54	HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence. *Immunogenetics*, **2016**, 68, 145-55	3.2	10
53	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. *AIDS Research and Human Retroviruses*, **2017**, 33, 859-868	1.6	9
52	Immune checkpoint modulation enhances HIV-1 antibody induction. *Nature Communications*, **2020**, 11, 948	17.4	9
51	Eliminating antibody polyreactivity through addition of N-linked glycosylation. *Protein Science*, **2015**, 24, 1019-30	6.3	8
50	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. *Journal of Virology*, **2018**, 92,	6.6	8
49	What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. *Cold Spring Harbor Perspectives in Biology*, **2018**, 10,	10.2	8
48	Computational analysis of antibody dynamics identifies recent HIV-1 infection. *JCI Insight*, **2017**, 2,	9.9	8
47	Vaccine Innovations - Past and Future. *New England Journal of Medicine*, **2021**, 384, 393-396	59.2	8
46	Novel Monoclonal Antibodies for Studies of Human and Rhesus Macaque Secretory Component and Human J-Chain. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*, **2016**, 35, 217-26	1.9	7

45	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure. *Journal of Virology*, **2021**,	6.6	7
44	Cold sensitivity of the SARS-CoV-2 spike ectodomain **2020**,		6
43	Protein/AS01 vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors. *Cell Reports Medicine*, **2021**, 2, 100207	18	6
42	Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice. *Journal of Immunology*, **2017**, 198, 1047-1055	5.3	5
41	Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. *Npj Vaccines*, **2020**, 5, 36	9.5	5
40	Subordinate Effect of -21M HLA-B Dimorphism on NK Cell Repertoire Diversity and Function in HIV-1 Infected Individuals of African Origin. *Frontiers in Immunology*, **2020**, 11, 156	8.4	5
39	HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. *Journal of Immunology*, **2016**, 197, 4663-4673	5.3	5
38	Lessons from babies: inducing HIV-1 broadly neutralizing antibodies. *Nature Medicine*, **2014**, 20, 583-5	50.5	5
37	The mouseCD7 gene: Identification of a new element common to the humanCD7 and mouseThy-1 promoters. *Immunogenetics*, **1996**, 44, 108-114	3.2	5
36	Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. *Journal of the International AIDS Society*, **2021**, 24 Suppl 7, e25831	5.4	5
35	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. *Npj Vaccines*, **2020**, 5, 107	9.5	5
34	Cross-Reactivity to Kynureninase Tolerizes B Cells That Express the HIV-1 Broadly Neutralizing Antibody 2F5. *Journal of Immunology*, **2019**, 203, 3268-3281	5.3	5
33	The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. *Nature Immunology*, **2021**, 22, 1294-1305	19.1	5
32	HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers. *Scientific Reports*, **2019**, 9, 10165	4.9	4
31	Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. *Vaccine*, **2014**, 32, 3995-4000	4.1	4
30	SARS-CoV-2 and HIV-1 - a tale of two vaccines. *Nature Reviews Immunology*, **2021**, 21, 543-544	36.5	4
29	Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans. *PLoS Pathogens*, **2019**, 15, e1008165	7.6	4
28	SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys **2021**,		4

27	Selection of HIV Envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. *Journal of Virology*, **2021**, JVI0164321	6.6	3
26	Development of mRNA Manufacturing for Vaccines and Therapeutics: mRNA Platform Requirements and Development of a Scalable Production Process to Support Early Phase Clinical Trials. *Translational Research*, **2021**,	11	3
25	Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 7929-7940	11.5	2
24	Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. *Journal of Virological Methods*, **2017**, 249, 85-93	2.6	2
23	Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination. *Current Opinion in Virology*, **2021**, 51, 172-178	7.5	2
22	Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial. *MBio*, **2020**, 11,	7.8	2
21	Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. *Journal of Virology*, **2020**, 94,	6.6	2
20	HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth. *Scientific Reports*, **2021**, 11, 14494	4.9	2
19	Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations. *Cell Reports*, **2021**, 36, 109561	10.6	2
18	mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice.. *Cell Reports*, **2022**, 38, 110514	10.6	2
17	Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials. *MSphere*, **2020**, 5,	5	1
16	Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX B/E in RV144 Vaccinees. *AIDS Research and Human Retroviruses* , **2014**, 30, A36-A36	1.6	1
15	The mouse CD7 gene: identification of a new element common to the human CD7 and mouse Thy-1 promoters. *Immunogenetics*, **1996**, 44, 108-114	3.2	1
14	Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. *Cell Reports*, **2021**, 37, 109922	10.6	1
13	Recapitulation of HIV-1 Env-Antibody Coevolution in Macaques Leading to Neutralization Breadth		1
12	Functional Improbable Antibody Mutations Critical for HIV Broadly Neutralizing Antibody Development		1
11	Response : HIV Viral Load Assay. *Science*, **1996**, 271, 1043-1043	33.3	1
10	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure		1

9	Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles **2021**,		1
8	Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity.. *Communications Biology*, **2022**, 5, 271	6.7	1
7	Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1. *Molecular Therapy - Methods and Clinical Development*, **2019**, 14, 148-160	6.4	0
6	How Does HIV Env Structure Informs Vaccine Design?. *Microscopy and Microanalysis*, **2020**, 26, 574-575	0.5	
5	HIV vaccine development at Duke University Medical Center. *Immunologic Research*, **2000**, 22, 263-9	4.3	
4	-Deficient Mice Exhibit Cytokine-Related Transcriptomic Signatures. *ImmunoHorizons*, **2020**, 4, 713-728	2.7	
3	Response : HIV Quasispecies and Resampling. *Science*, **1996**, 273, 416-416	33.3	
2	Response : HIV Viral Load Assay. *Science*, **1996**, 271, 1043-1043	33.3	
1	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. *PLoS Pathogens*, **2021**, 17, e1009624	7.6	